Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MRLA @ .22: FaceBook"s Jeff Zuckerberg on it. Melanoma detect via phone app.
MRLA just closed a private placement in Israel for .40 a share that went unnoticed in USA.
MRLA starting to get gloabal attention, including Zuckerberg talking about the tech in a recent speech, without mentioning the MRLA company name.
Do your DD.
Great science. Big names involved and full support of the Israeli governments medical agencies.
Big one
FaceBook: Zuckerberg:
https://www.accesswire.com/439481/Zuckerberg-Marks-Artificial-Intelligence-as-Next-Wave-of-Healthcare-Reports-Emerald-Medical-Applications-Corp
MRLA DermaCompare website:
http://www.dermacompare.com/
CRTN @ $1.10: Turnaround confirmation 10-K due 3/29. 100% pop.
Most observers expect the paperwork to confirm the return to full profit.
CRTN low float & profitable. Likely moves much higher in coming sessions.
10-K due news:
http://finance.yahoo.com/news/cartesian-sets-fourth-quarter-full-120000895.html
1/20/17:
http://finance.yahoo.com/news/cartesian-reports-continued-growth-network-130100696.html
CRTN @ $1.06: 10-K due 3/29: Likely posts serious profit.
Most observers expect the paperwork to confirm the return to full profit.
CRTN low float & profitable. Likely moves much higher in coming sessions.
10-K due news:
http://finance.yahoo.com/news/cartesian-sets-fourth-quarter-full-120000895.html
1/20/17:
http://finance.yahoo.com/news/cartesian-reports-continued-growth-network-130100696.html
CRTN @ $1.06: 10-K due 3/29: Likely posts serious profit.
Most observers expect the paperwork to confirm the return to full profit.
CRTN low float & profitable. Likely moves much higher in coming sessions.
10-K due news:
http://finance.yahoo.com/news/cartesian-sets-fourth-quarter-full-120000895.html
1/20/17:
http://finance.yahoo.com/news/cartesian-reports-continued-growth-network-130100696.html
MRLA @ .19. Pounding away.
Bought more this morning.
Also, CRTN should post 10-K date and subsequent 10-K with killer numbers at any time. Likely moves over $2.00 range on news.
And top oil play CEGX is getting hot. The oil crowd is sending it now. Multi-bags from the same folks that sent MMEX and a few others. They are on CEGX now and the company just retired 250M shares.
CEGX: Quietly loaded up. 25 bagger on tap.
Slammed some big ones in the oil patch over the years.
CEGX another solid shot in coming sessions.
Put a few Gs in here and pocket serious cash going forward.
Beauty. I am loaded.
OVAS @ 1.67:Oprah rumor gaining momo.
OVAS has a lot of cash and a game changing pipeline.
Well worth putting on screen
MRLA @ .25. Algo detects skin cancer via any smartphone.
Low float & Jeff Zuckerberg is on it.
One of the big plays. A Nasdaq like stock heading into multi-$$ range.
Link:
http://www.dermacompare.com/
NOTE: MRLA just closed a private stock sale @ .40 cents a in Israel.
http://www.news9.com/story/34716552/emerald-medical-applications-announces-closing-of-stock-purchase-agreement-with-publicis-groupe-at-040-per-share
MRLA @ .25. Algo detects skin cancer via any smartphone.
Low float & Jeff Zuckerberg is on it.
One of the big plays. A Nasdaq like stock heading into multi-$$ range.
Link:
http://www.dermacompare.com/
NOTE: MRLA just closed a private stock sale @ .40 cents a in Israel.
http://www.news9.com/story/34716552/emerald-medical-applications-announces-closing-of-stock-purchase-agreement-with-publicis-groupe-at-040-per-share
MRLA @ .25: Skin cancer using Smartphone & algo.
Zuckerberg likes it.
Do DD.
Big play on low float.
CRTN @ $1.16: Killer 10-K due. Much higher next two weeks.
Low float & only profitable Nasdaq play trading under $4.00
MRA @ .25: Skin cancer detected via smartphone camera. Zuckerbeg on board.
Do you DD..
Low float
MRLA@ .23. Facebooks Zuckerberg buying it?
Low float Nasdaq-like play.
Algo detects skin cancer via smartphone pic better than doctor
MRLA on the buyout calender now
MRLA @ .24. Table pounder. Headed over $1.00.
MRLA about to get very hot.
Low float and tightly held.
Just a great play.
MRLA @ .23. Secondary @ .40. Low floater.
A Nasdaq like play.
AI tech. Makes any smartphone a skn cancer detector better than any doctor.
Mark Zuckerberg on this one.
See news and load up.
Big
MRLA @ .23. Seondary just closed @
.40
Tiny float. More like Nasdaq play.
Uses algo for smartphones to diagnose skin cancer.
Zuckerberg just talked about it and AI in San Francisco
MRLA moving up but will go very big in coming sessions.
See news.
MRLA @ .23. Seondary just closed .40 a share.
See news.
Low floater. More like a Nasdaq play.
Zuckerberg interested in buyout.
Use smartphone to diagnose skin cancer via algo software.
Big one.
MRLA@ .19. Secondary closed @ .40 last week
See news.
Low floater, Nasdaq quality.
Algo for smart phones that detects skin cancer. Zuckerberg a fan
Buyout likely.
INPX:Micro-float target. Special Situation play.
Symbol change from SYRX & 1-15 reverse split done.
Another CRTN but bigger move.
Watch how hot this one gets
SGMO:FDA grants Orphan Drug Status. Not on news wires or PR yet.
CRTN @ $1.11:10-K double due.
All indication are for a sterling report and forward guidance.
Just a beauty right now.
LIFE: FDA approved Orphan Drug Status. Not on news wires yet.
For MS drug.
News posted on FDA site today.
LIFE has tons of cash and very strong pipeline.
Low float too.
When FDA news hits news wires LIFE is going to move up strong, imo.
LIFE: FDA approved Orphan Drug Status. Not on news wires yet.
For MS drug.
News is posted on FDA site.
Buy now and prosper.
LIFE: FDA approves Orphan Drug Status. No PR. Yet.
For MS drug.
News only on FDA site right now.
LIFE a low floater with lots of cash
When FDA news hits news wires this will be big news, imo.
LIFE: FDA approves Orpan Drug Status. No PR posted yet.
MS drug.
LIFE has very strong cash and major pipeline.
Big FDA support too.
Now, major FDA news issued today on FDA site but not yet on news wires.
Low floater too.
Big move as news becomes known
LIFE: FDA grants Orphan Drug Status for MS. No PR yet.
News not yet posted.
LIFE has tons of cash , great pipe line with strong FDA support.
Now FDA news today that few aew aware of.
Very nice indeed.
NWAV: Walmart deal in Ohio & Florida?
Makes total sense for Walmart to roll out in these big states.
NWAV: Fla. clinic accepting patients.
Staff taking patient insurance info and accepting referrals.
Big.
NWAV: Fla. clinic accepting patients.
Staff taking patient insurance info and accepting referrals.
Big.
NWAV: Big media attention in Fla next week for opening.
Some of the buying is from the publicity already being generated.
Next week will be much bigger deal.
NWAV about to get super hot, imo.
NWAV:Many cars at Fla facility. Wild
Buy big herer. I did
RXII @ .75....CLSN @ .36 ...Next
GALT @ $1.28: Wants to break higher.
One of the big players may take this one out.
Website:
http://galectintherapeutics.com/
GALT @ $1.28: Wants to break higher.
One of the big players may take this one out.
Website:
http://galectintherapeutics.com/
CLSN @ .36. Best play of day. May pop nicely here.
Link:
http://finviz.com/quote.ashx?t=clsn
RXII @ .65. Lo float, cash. May pop.
Finished financing.
Likely target for the small cap crowd that has been launching these babies.
Website:
http://www.rxipharma.com/
RXII @ .65. Lo float, cash. May pop.
Finished financing.
Likely target for the small cap crowd that has been launching these babies.
Website:
http://www.rxipharma.com/
GOVX: " The 50 most Important People in Vaccines"
#22 is Dr Farshad Guirakhoo, GeoVax Chief Science Officer.
#2 is Dr. Thomas Monath, recently installed as Chairman of the GeoVax Science Advisory Board. He is credited with the recent development of the 100% effective Ebola vax for NLNK & Merck.
Link:
http://www.paxvax.com/about/news/vaccinenation-names-paxvax-cto-dr-thomas-monath-2-most-influential-person-in-vaccines
NOTE: Impressive for a .06 cent stock with a $3.2M market cap.
GOVX: " The 50 most Important People in Vaccines"
#22 is Dr Farshad Guirakhoo, GeoVax Chief Science Officer.
#2 is Dr. Thomas Monath, recently installed as Chairman of the GeoVax Science Advisory Board. He is credited with the recent development of the 100% effective Ebola vax for NLNK & Merck.
Link:
http://www.paxvax.com/about/news/vaccinenation-names-paxvax-cto-dr-thomas-monath-2-most-influential-person-in-vaccines
NOTE: Impressive for a .06 cent stock with a $3.2M market cap.
GOVX: Fed Zika $$ now being distributed.
In December, 2016, the CDC handed over $200M to the States.
Link:
http://www.calcalist.co.il/local/articles/0,7340,L-3707261,00.html
States are now handing out cash:
http://miami.cbslocal.com/2017/02/02/florida-awards-grants-in-battle-against-zika-virus/
So, GOVX will likely get Zika cash at any time from the State of Georgia or directly from the CDC. It is possible that GOVXs Zika partner, the University of Georgia will get State cash and GeoVax will get direct CDC cash.
U of Georgia & Geovax:
http://news.uga.edu/releases/article/university-of-georgia-geovax-zika-vaccine-0216/
NOTE: The CDC has a few hundred million $$ in Zika funding to hand out besides the grants to the States. Imo, that is where GeoVax is going to get the Zika payday.